Navigation Links
iBio Announces New US Patent for iBioLaunch™ Technology
Date:10/31/2011

NEWARK, Del., Oct. 31, 2011 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced notice of issuance from the United States Patent and Trademark Office for US Patent 8,058,511, entitled "System for Expression of Genes in Plants," that further extends iBio's patent coverage of viral vectors comprising its iBioLaunch™ platform. This proprietary technology owned by iBio was developed by scientists at iBio's research collaborator, the Fraunhofer USA Center for Molecular Biotechnology (Fraunhofer).

"The issuance of this patent substantially strengthens the intellectual property foundation of the iBioLaunch system for simultaneously expressing more than a single protein," said Terence Ryan, Ph.D., iBio's Senior Vice-President. "For example, this patent protects the technology we use for production of human monoclonal antibodies, a rapidly growing pharmaceutical category in which we recently announced successful product candidate testing."

iBio is commercializing its technology by establishing licenses or other collaboration arrangements both for biosimilar products and proprietary products. In January 2011, iBio and Fraunhofer entered into a License and Collaboration Agreement with Fiocruz/ Bio-Manguinhos, an entity linked to the Health Ministry of Brazil, for the development and sale of a proprietary Yellow Fever Vaccine based upon the IBioLaunch technology, to replace the chicken egg based vaccine that Fiocruz has been producing and supplying to Brazil and more than 60 other nations. Since then, iBio has been advancing and making available other candidate products based on the iBioLaunch platform for similar license and collaboration arrangements.  

The broad range of iBioLaunch-produced product candidates in clinical or preclinical development include:  (i) human alpha-galactosidase for treatment of Fabry disease, (ii) the proteins C1
'/>"/>

SOURCE iBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. Anesiva Announces Second Quarter 2008 Financial Results and Update
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
7. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
8. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
11. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Terascala, the industry leader in ... a former vice president of product management for Flexera ... of marketing. Terascala’s software when combined with leading compute ... highest performance and most reliable solutions for processing big ... channel expansion and broaden its product portfolio. His leadership ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 OMICS Group’s ... techniques during 18-20 August, 2014 at Double Tree by ... the recent developments in Analytical & Bioanalytical research methods ... , Speaking on this occasion, Dr. Srinubabu Gedela, MD ... Acta conference is a remarkable one in bringing a ...
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
(Date:7/10/2014)... Utah , July 10, 2014 /PRNewswire-iReach/ ... annotation and interpretation, today announced an agreement ... (NGS) analytics for Lineagen,s NextStep Dx ... of neurodevelopmental and neurological disorders, currently offers ... microarray (CMA) testing service used by healthcare ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... Researchers in India have demonstrated that producing nanoscopic crystals of ... by the gut even if the drug is not soluble ... the medicinal drugs being developed by the pharmaceutical industry dissolve ... a major problem for administering such drugs as it means ...
... ANGELES, Oct. 6 Entertain and interact.  That,s ... . ( www.drfresh.com ), the creator of the ... company behind the successful revival of the ... http://photos.prnewswire.com/prnh/20101006/LA77977LOGO ) (Logo:   http://www.newscom.com/cgi-bin/prnh/20101006/LA77977LOGO ) ...
... Inc. Against the Company And Certain of Its Subsidiaries ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
Cached Biology Technology:Nano drugs 2A 'Fresh' Approach to Marketing: Dr. Fresh™, Inc. Goes Guerilla With Internet-Based Campaigns 2Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 2Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 3Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 4Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 5Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 6Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 7Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 8Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 9
(Date:7/13/2014)... New research raises the prospect of more effective ... muscle occurring in about half of all cancer patients, ... Dana-Farber Cancer Institute. , Many strategies have been tried ... that patients can,t endure potentially life-saving treatments, but none ... July 13 advanced online edition of Nature , ...
(Date:7/11/2014)... Society shows that no-take zones in Belize can ... lobster, conch, and fish recover from overfishing, but ... The reporttitled "Review of the Benefits of No-Take ... no-take areas around the world. The report was ... in marine protected areas and fisheries management. The ...
(Date:7/11/2014)... at the Department of Energy,s Oak Ridge National ... by R&D Magazine in recognition of the year,s ... the tremendous value of our National Labs," said ... at the National Labs continues to help our ... scientific and technological innovations necessary to remain globally ...
Breaking Biology News(10 mins):Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... and under-diagnosed genetic disease in humans just may be ... College of Georgia researchers report. They are pursuing a ... wet form of macular degeneration, the leading cause of blindness ... iron, known to wreak cumulative havoc on the body,s organs, ...
... the tenth anniversary of the completion of the first draft of ... to complete the Wellcome Trust today launches a project to ... This will be one of the largest genome sequencing programmes ever ... in 6,000 people in the UK. The UK10K project is ...
... in German . , Missour/Leipzig. In ... African bird species with a very distinctive courtship behaviour, ... of the same species positively affects brooding females, improving ... birds in the experiment were more fertile and had ...
Cached Biology News:Link between iron overload and macular degeneration under study 2Link between iron overload and macular degeneration under study 3Ten years on, Wellcome Trust launches study of 10,000 human genomes in UK 2Ten years on, Wellcome Trust launches study of 10,000 human genomes in UK 3Pleasing to the eye 2Pleasing to the eye 3
... CTI Molecular Imaging's proprietary Focus™ detector ... and a large imaging volume that ... image multiple mice or large primateswithout ... dedicated small animal PET (Positron Emission ...
...
These 18x18 square No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick....
...
Biology Products: